Past, Present and Future of Population Proteomics

In the last half decade, we have witnessed an exponential increase in the sample sizes of multiplex proteomics studies, with population biobanks in Iceland, Finland, Qatar, and the United Kingdom increasingly implementing proteomic profiling across their cohorts. In this talk, we will illustrate how the rapidly expanding field population proteomics has emerged from, and has been partly driven by, the successes and setbacks of population genetics. We will review present-day examples of how population proteomics is being leveraged to accelerate precision medicine, placing particular emphasis on high-impact applications of the UK Biobank Pharma Proteomics Project (UKB-PPP) dataset. Finally, we will discuss the  future of population proteomics – from more systematic integration into the drug development process to clinical translation